MyoKardia Launches with $38M; Tackles Genetic Heart Disease
By Jennifer Boggs
Thursday, September 20, 2012
The latest firm launched by Third Rock Ventures, MyoKardia Inc., started its existence with a $38 million Series A financing, disclosed Thursday morning, to translate discoveries of mutations in the heart muscle into personalized therapeutic approaches for treating genetic cardiomyopathy.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.